SYGNIS significantly expands its Asian distribution network by signing three additional agreements with PhileKorea and Pharma Tech Korea as well as Axil Scientific for Singapore
- SYGNIS’ new partners are industry leading distributors focused on molecular biology, protein research, cell biology and diagnostics
- Agreements cover the entire SYGNIS portfolio of powerful tools for next generation sequencing (NGS), single cell analysis (SCA) and liquid biopsies applications
Madrid, Spain and Heidelberg, Germany, December 17, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed three additional non-exclusive distribution agreements with PhileKorea, Pharma Tech Korea and Axil Scientific for the commercialization of SYGNIS’ proprietary product portfolio in Korea and Singapore and thereby significantly expands its Asian footprint.
With these agreements, SYGNIS grants non-exclusive rights to promote, market and sell all existing as well as future product lines to scientists working in genomics, proteomics and diagnostics in Korea and Singapore. These product lines cover the Company’s revolutionary TruePrimeTM products for primer-free whole genome amplification (WGA) as well as SunScriptTM thermostable reverse transcriptase kits for the translation of RNA into DNA including the newly launched SunScriptTM One Step Reverse Transcriptase (RT)- PCR Kit for parallel transcription and amplification of genomic information.
“We are very pleased about these distribution agreements for our proprietary product portfolio with industry leading partners in the growing life science markets of Korea and Singapore,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “After we successfully announced distributions agreements for the US just two weeks ago, we today were able to significantly expand our footprint in the Asian markets. We are very focused and committed to further building up and expanding our distribution channel program in 2016 in order to make our products widely available.”
Visit our website for additional information on SYGNIS products: http://www.sygnis.com.
TruePrimeTM is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrimeTM is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
SunScriptTM RT is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScriptTM Reverse Transcriptase will be available in two versions: SunScriptTM RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions for use e.g. in clinical diagnostics whereas SunScriptTM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing (NGS) applications, in gene expression profiling and molecular diagnostics.
For further information please contact:
Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Phone: +49 89 210228 30